# US 2022/0031867 A1 · Glymphatic delivery by manipulating plasma osmolarity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031867 A1
- Document ID: US20220031867A1
- Status: Published application
- Kind: A1
- Application number: 17/280,606
- Filed: 2019-09-30
- Published: 2022-02-03
- Earliest claimed: 2018-10-04
- Assignees: University of Rochester
- Applicants: University of Rochester
- Inventors: Maiken Nedergaard; Benjamin Plog; Humberto Mestre
- Web page: https://patentgrep.com/patent/US20220031867A1

## CPC

- A61B 5/0042: {for the brain}
- A61K 49/0058: {Antibodies}
- A61B 5/0077: {Devices for viewing the surface of the body, e.g. camera, magnifying lens}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61M 5/00: Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests (tube connectors, tube couplings, valves or branch units, specially adapted for medical use A61M39/00; containers specially adapted for medical or pharmaceutical purposes A61J1/00)
- A61P 25/00: Drugs for disorders of the nervous system
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to improving delivery of agents to the central nervous system.

## Claims

### Claim 1

A method for improving delivery of a composition to a central nervous system interstitium, brain interstitium and/or a spinal cord interstitium of a subject comprising:
(1) enhancing glymphatic system influx; and
(2) delivering the composition to the central nervous system interstitium, brain interstitium and/or the spinal cord interstitium,
wherein the step of enhancing glymphatic system influx comprises administering a hypertonic solution agent into plasma of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the step of enhancing glymphatic system influx further comprises pumping fluid through the central nervous system interstitium.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the hypertonic solution comprises NaCl or Mannitol.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is delivered intracisternally or intrathecally.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is delivered at about the same time or after the glymphatic system influx is enhanced.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is an imaging composition.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is a therapeutic composition.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition comprises a small molecule, a virus, a large molecule, a peptide, an antibody, a nucleic acid, or a biologically active fragment thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the therapeutic composition comprises an antibody.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antibody is conjugated to a ligand that facilitates transport across the blood brain barrier (BBB).

### Claim 14 (depends on 13)

The method of claim 13, wherein the ligand specifically binds to a blood-brain barrier (BBB) receptor.

### Claim 15

A method for treating a neurological disorder in a subject, comprising
(1) enhancing glymphatic system influx; and
(2) delivering a therapeutic composition to the central nervous system interstitium, brain interstitium and/or the spinal cord interstitium,
wherein the step of enhancing glymphatic system influx comprises administering a hypertonic solution agent into plasma of the subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the step of enhancing glymphatic system influx further comprises pumping fluid through the central nervous system interstitium.

### Claim at position 16

17-18. (canceled)

### Claim 19 (depends on 15)

The method of claim 15, wherein the hypertonic solution comprises NaCl or Mannitol.

### Claim 20

(canceled)

### Claim 21 (depends on 15)

The method of claim 15, wherein the composition is delivered intracisternally or intrathecally.

### Claim 22 (depends on 15)

The method of claim 15, wherein the composition is delivered at about the same time or after the glymphatic system influx is enhanced.

### Claim 23 (depends on 15)

The method of claim 15, wherein the therapeutic composition comprises a small molecule, a virus, a large molecule, a peptide, an antibody, a nucleic acid, or a biologically active fragment thereof.

### Claim 24 (depends on 23)

The method of claim 23 wherein the therapeutic composition comprises an antibody.

### Claim 25 (depends on 24)

The method of claim 24, wherein the antibody is conjugated to a ligand that facilitates transport across the blood brain barrier.

### Claim 26 (depends on 25)

The method of claim 25, wherein the ligand specifically binds to a BBB receptor

### Claim 27 (depends on 24)

The method of claim 24, wherein the antibody is an anti-Aβ antibody.

### Claim 28 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 29 (depends on 28)

The method of claim 28, wherein the mammal is a human or a non-human primate.

### Claim at position 28

30-31. (canceled)

### Claim 32 (depends on 15)

The method of claim 15, wherein the neurological disorder is selected from the group consisting of a neuropathy, an amyloidosis, cancer, an ocular disease or disorder, a viral or microbial infection, inflammation, ischemia, neurodegenerative disease, seizure, behavioral disorder, and lysosomal storage disease.

### Claim 33 (depends on 1)

A kit for improving delivery of a composition to the central nerve system (CNS) of a subject, comprising the composition and hypertonic agent of claim 1.

### Claim at position 31

34-45. (canceled)
